Table 4.
Biological activities of mono-, di-, and poly-sulfated steroids.
| No. | Antitumor & Related Activity, (Pa) * | Violation of Lipid Metabolism, (Pa) * | Additional Predicted Activity, (Pa) * |
|---|---|---|---|
| 48 | Chemopreventive (0.913) Antineoplastic (0.844) |
Anti-hypercholesterolemic (0.825) Cholesterol synthesis inhibitor (0.678) |
Hepatoprotectant (0.924) Biliary tract disorders treatment (0.727) |
| 49 | Antineoplastic (0.716) | Anti-hypercholesterolemic (0.865) | Biliary tract disorders treatment (0.794) |
| 50 | Antineoplastic (0.686) | Anti-hypercholesterolemic (0.679) | Hepatoprotectant (0.653) |
| 51 | Antineoplastic (0.626) | Cholesterol antagonist (0.820) | Anti-inflammatory (0.614) |
| 52 | Antineoplastic (0.691) | Cholesterol antagonist (0.934) | Antifungal (0.696) |
| 53 | Antineoplastic (0.874) | Anti-hypercholesterolemic (0.697) | Anti-inflammatory (0.718) |
| 54 | Antineoplastic (0.849) | Atherosclerosis treatment (0.748) | Anti-inflammatory (0.777) |
| 55 | Antineoplastic (0.869) | Autoimmune disorders treatment (0.762) | Angiogenesis inhibitor (0.926) |
| 56 | Antineoplastic (0.796) | Atherosclerosis treatment (0.646) | Anti-inflammatory (0.811) |
| 57 | Antineoplastic (0.836) Chemopreventive (0.712) Apoptosis agonist (0.649) |
Atherosclerosis treatment (0.684) Cholesterol synthesis inhibitor (0.656) Anti-hypercholesterolemic (0.617) |
Biliary tract disorders treatment (0.928) Hepatic disorders treatment (0.889) Wound-healing agent (0.888) |
| 58 | Antineoplastic (0.788) | Cholesterol synthesis inhibitor (0.755) | Biliary tract disorders treatment (0.843) |
| 59 | Antineoplastic (0.793) | Atherosclerosis treatment (0.636) | Biliary tract disorders treatment (0.713) |
| 60 | Antineoplastic (0.782) | Cholesterol synthesis inhibitor (0.671) | Wound-healing agent (0.933) |
| 61 | Antineoplastic (0.820) | Cholesterol synthesis inhibitor (0.734) | Wound-healing agent (0.942) |
| 62 | Antineoplastic (0.711) | Cholesterol synthesis inhibitor (0.696) | Biliary tract disorders treatment (0.963) |
| 63 | Antineoplastic (0.764) | Atherosclerosis treatment (0.684) | Biliary tract disorders treatment (0.957) |
| 64 | Chemopreventive (0.948) | Cholesterol synthesis inhibitor (0.562) | Hepatoprotectant (0.915) |
| 65 | Antineoplastic (0.729) | Cholesterol synthesis inhibitor (0.572) | Biliary tract disorders treatment (0.835) |
| 66 | Antineoplastic (0.734) | Cholesterol synthesis inhibitor (0.661) | Biliary tract disorders treatment (0.725) |
| 67 | Antineoplastic (0.790) | Cholesterol synthesis inhibitor (0.655) | Wound-healing agent (0.812) |
| 68 | Antineoplastic (0.868) | Atherosclerosis treatment (0.645) | Hepatoprotectant (0.918) |
| 69 | Antineoplastic (0.868) | Atherosclerosis treatment (0.645) | Hepatoprotectant (0.918) |
| 70 | Antineoplastic (0.748) Chemopreventive (0.692) |
Cholesterol synthesis inhibitor (0.688) Atherosclerosis treatment (0.664) |
Biliary tract disorders treatment (0.943) Hepatic disorders treatment (0.934) |
| 71 | Antineoplastic (0.767) Chemopreventive (0.704) |
Cholesterol synthesis inhibitor (0.696) Atherosclerosis treatment (0.665) |
Biliary tract disorders treatment (0.963) Hepatic disorders treatment (0.934); |
* Only activities with Pa > 0.5 are shown.